Modern aspects of anti-viral therapy for hepatitis D
Viral hepatitis D (HDV infection) worsens the prognosis of HBV infection course in 80-90% of cases, accelerating fibrosis and leading to liver cirrhosis or hepatocellular carcinoma. Hepatitis D affects at least 125 000 people in Russia, and in the world, according to rough estimates, there are 15–20...
Saved in:
Main Authors: | A. S. Zheleznova, K. A. Svirin, M. Yu. Kartashov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Journal Infectology
2024-09-01
|
Series: | Журнал инфектологии |
Subjects: | |
Online Access: | https://journal.niidi.ru/jofin/article/view/1659 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Is Combined Bulevirtide and Pegylated Interferon Therapy for Chronic Hepatitis D Superior over Bulevirtide Monotherapy?
by: V. E. Syutkin, et al.
Published: (2020-09-01) -
Lack of Tissue Virological Response as a Predictor of Relapse in Chronic Hepatitis D after Completion Bulevirtide Therapy
by: P. O. Bogomolov, et al.
Published: (2024-12-01) -
National representative seroprevalence of viral hepatitis B, C, and D seromarkers in Ukraine, 2021
by: Olena Nesterova
Published: (2025-07-01) -
Modern etiotropic therapy of chronic viral hepatitis B
by: E. B. Bun'kova, et al.
Published: (2024-10-01) -
Genotypic Diversity of Hepatitis C Virus in Tuberculosis Patients in the Tomsk Region
by: K. A. Svirin, et al.
Published: (2025-03-01)